Mason W P, Krol G S, DeAngelis L M
Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Neurology. 1996 Jan;46(1):203-7. doi: 10.1212/wnl.46.1.203.
We administered chemotherapy in standard and intensified formulations of procarbazine, lomustine (CCNU), and vincristine to nine symptomatic patients with low-grade oligodendroglioma. Eight patients were treated with chemotherapy at presentation and one was treated for a recurrence after radiotherapy had failed. All patients improved by clinical or MRI criteria, or both. No patient deteriorated while in therapy and the responses were sustained without radiotherapy for a median of 35 months (range, 22-45) in all surviving patients treated at presentation. Chemotherapy was well tolerated; all patients developed myelosuppression, but only those receiving the intensified regimen required dose reduction or premature discontinuation of treatment. As with recurrent and anaplastic oligodendroglioma, low-grade oligodendroglioma responds to chemotherapy.
我们对9例有症状的低级别少突胶质细胞瘤患者给予了标准和强化方案的丙卡巴肼、洛莫司汀（CCNU）及长春新碱化疗。8例患者在初诊时接受化疗，1例在放疗失败后复发时接受治疗。所有患者依据临床或MRI标准，或两者均有改善。治疗期间无患者病情恶化，初诊时接受治疗的所有存活患者在未接受放疗的情况下，缓解持续时间的中位数为35个月（范围22 - 45个月）。化疗耐受性良好；所有患者均出现骨髓抑制，但只有接受强化方案的患者需要减量或提前终止治疗。与复发型和间变性少突胶质细胞瘤一样，低级别少突胶质细胞瘤对化疗有反应。
